Moody's Investors Service warned yesterday it could strip Pfizer of its top-notch credit rating. The move could force the US pharmaceuticals giant to pay more if it turns to the debt markets to finance a bid for Boots Healthcare International.

Moody's placed Pfizer's triple-A rating on review for downgrade after the US giant was forced to suspend sales of its Bextra drug and withdraw its Celebrex drug.